Ooze

Ooze Bio is a San Diego-based biotechnology company focused on developing next-generation therapies for obesity and metabolic diseases. The company was founded in 2023 by a veteran leadership team including Sheila Gujrathi and Faheem Hasnain, who previously led Receptos and Gossamer Bio. Ooze Bio's primary focus is on the discovery and development of potent, oral small molecule agonists for the glucagon-like peptide 1 receptor (GLP-1R). By leveraging their expertise in G-protein coupled receptor (GPCR) biology, the team aims to create weight-loss treatments with improved patient convenience and metabolic profiles. The company is backed by prominent venture capital firms, including ARCH Venture Partners and OrbiMed, having raised significant early-stage funding. Ooze Bio operates within the highly competitive incretin-based therapy space, seeking to differentiate its candidates through superior drug properties and clinical design.